{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "69-year-old Japanese woman diagnosed with clinical stage IV (T2aN2M1b in 7th edition) lung adenocarcinoma with pleural and bone metastasis. EGFR gene mutation was not detected in malignant pleural effusion by real-time polymerase chain reaction (PCR).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Lung cancer, unspecified",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C79.9",
              "label": "Secondary malignant neoplasm of unspecified site",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C79.51",
              "label": "Secondary malignant neoplasm of bone",
              "status": "active",
              "onset_date": null
            }
          ],
          "imaging": [
            {
              "type": "Pleural effusion",
              "body_part": "Pleura",
              "modality": "other",
              "finding": "malignant",
              "impression": "malignant pleural effusion",
              "date": null
            }
          ],
          "social_history": [
            {
              "category": "other",
              "status": "unknown",
              "description": "Japanese ethnicity"
            }
          ],
          "labs": [
            {
              "test": "EGFR gene mutation",
              "value": "not detected",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Started carboplatin, paclitaxel, and bevacizumab as the first-line treatment.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0007127",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0030384",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1263454",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Pemetrexed administered as second-line treatment.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0974083",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Erlotinib administered as third-line treatment.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1296534",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Docetaxel administered as fourth-line treatment.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0013087",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Lung cancer progressed with increased pleural effusion after one cycle with gemcitabine (fifth-line treatment). EGFR gene mutation studied in pleural effusion using PCR fragment analysis/PCR clamp method revealed a deletion in exon 19 and a T790M point mutation in exon 20.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34",
              "label": "Lung cancer",
              "status": "active"
            }
          ],
          "labs": [
            {
              "test": "EGFR gene mutation",
              "value": "deletion in exon 19 and a T790M point mutation in exon 20",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null
            }
          ],
          "imaging": [
            {
              "type": "Pleural Effusion",
              "body_part": "Lung",
              "modality": null,
              "finding": "increased",
              "impression": null
            }
          ],
          "medications": [
            {
              "drug": "Gemcitabine",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "indication": "Lung cancer"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Afatinib started as sixth-line treatment with a PFS of 4.0 months. Afatinib treatment continued for 15.3 months (458 days).",
        "clinical_data": {
          "medications": [
            {
              "drug": "Afatinib",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "At 74 years old, patient started osimertinib (80 mg/day) as seventh-line treatment. BMI 16.2 kg/cm2, performance status of 1.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1608371",
              "dosage": "80 mg/day",
              "frequency": "daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": "seventh-line treatment"
            }
          ],
          "vitals": [
            {
              "type": "Body Mass Index",
              "value": "16.2",
              "unit": "kg/cm2",
              "timestamp": null
            }
          ],
          "functional_status": [
            {
              "domain": "general",
              "description": "performance status of 1"
            }
          ],
          "social_history": [
            {
              "category": "age",
              "status": "current",
              "description": "74 years old"
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Developed grade 1 cutaneous pruritus and stomatitis (CTCAE ver 4.0) as adverse events from osimertinib.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0234319",
              "label": "Pruritus",
              "status": "active"
            },
            {
              "code": "C0038424",
              "label": "Stomatitis",
              "status": "active"
            }
          ],
          "medications": [
            {
              "drug": "C3888713",
              "indication": "Adverse event"
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "Gradual improvement in shoulder pain from bone metastasis while on osimertinib.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0376358",
              "label": "bone metastasis",
              "status": "active"
            }
          ],
          "medications": [
            {
              "drug": "C3888714",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "HPI": [
            {
              "summary": "Gradual improvement in shoulder pain",
              "duration": null,
              "onset": null,
              "progression": "gradual",
              "associated_symptoms": [
                "C0036859"
              ],
              "alleviating_factors": [],
              "exacerbating_factors": []
            }
          ]
        }
      }
    },
    {
      "id": "N11",
      "label": "Step 11",
      "customData": {
        "node_id": "K",
        "node_step_index": 10,
        "content": "Oxycodone stopped on the 87th day after osimertinib was started.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0030186",
              "end_date": "P87D",
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N12",
      "label": "Step 12",
      "customData": {
        "node_id": "L",
        "node_step_index": 11,
        "content": "Best response to osimertinib was stable disease.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0549048",
              "label": "Stable Disease",
              "status": "active"
            }
          ],
          "medications": [
            {
              "drug": "C1621494",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N13",
      "label": "Step 13",
      "customData": {
        "node_id": "M",
        "node_step_index": 12,
        "content": "Follow-up CT at day 97 after treatment with osimertinib showed intra-mural air in the transverse colon and intra-hepatic portal vein gas, suggestive of pneumatosis intestinalis. No free air in the abdominal cavity. Lung cancer did not progress.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Computed tomography",
              "body_part": "Transverse colon",
              "modality": "CT",
              "finding": "Intra-mural air",
              "date": "unknown"
            },
            {
              "type": "Computed tomography",
              "body_part": "Intra-hepatic portal vein",
              "modality": "CT",
              "finding": "Intra-hepatic portal vein gas",
              "impression": "Pneumatosis intestinalis",
              "date": "unknown"
            },
            {
              "type": "Computed tomography",
              "body_part": "Abdominal cavity",
              "modality": "CT",
              "finding": "No free air",
              "date": "unknown"
            },
            {
              "type": "Computed tomography",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "Lung cancer did not progress",
              "date": "unknown"
            }
          ]
        }
      }
    },
    {
      "id": "N14",
      "label": "Step 14",
      "customData": {
        "node_id": "N",
        "node_step_index": 13,
        "content": "Abdominal computed tomography showed intra-mural gas in the wall of the transverse colon and intra-hepatic portal vein gas in the peripheral area of the liver. White blood cell count was 3500/\u03bcL (normal range: 3400-9200/\u03bcL)",
        "range": 0.0,
        "clinical_data": {
          "labs": [
            {
              "test": "White blood cell count",
              "value": "3500",
              "unit": "/\u03bcL",
              "flag": "normal",
              "reference_range": "3400-9200/\u03bcL"
            }
          ],
          "imaging": [
            {
              "type": "Computed tomography of abdomen",
              "body_part": "abdomen",
              "modality": "CT",
              "finding": "intra-mural gas in the wall of the transverse colon and intra-hepatic portal vein gas in the peripheral area of the liver"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Initiation of first-line treatment for stage IV lung adenocarcinoma."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Progression on first-line treatment, leading to second-line treatment."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Progression on second-line treatment, leading to third-line treatment."
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Progression on third-line treatment, leading to fourth-line treatment."
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Progression on fourth-line treatment, leading to fifth-line treatment with gemcitabine and subsequent disease progression with increased pleural effusion. EGFR mutation analysis reveals exon 19 deletion and T790M mutation."
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Following identification of EGFR mutations, sixth-line treatment with afatinib is initiated."
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Following Afatinib treatment, seventh-line treatment with osimertinib is initiated."
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Development of grade 1 cutaneous pruritus and stomatitis as adverse events from osimertinib."
      }
    },
    {
      "from": "N9",
      "to": "N10",
      "data": {
        "edge_id": "I_to_J",
        "branch_flag": true,
        "content": "Gradual improvement in shoulder pain from bone metastasis while on osimertinib."
      }
    },
    {
      "from": "N10",
      "to": "N11",
      "data": {
        "edge_id": "J_to_K",
        "branch_flag": true,
        "content": "Oxycodone stopped on the 87th day after osimertinib was started."
      }
    },
    {
      "from": "N11",
      "to": "N12",
      "data": {
        "edge_id": "K_to_L",
        "branch_flag": true,
        "content": "Best response to osimertinib was stable disease."
      }
    },
    {
      "from": "N12",
      "to": "N13",
      "data": {
        "edge_id": "L_to_M",
        "branch_flag": true,
        "content": "Follow-up CT at day 97 after treatment with osimertinib showed intra-mural air in the transverse colon and intra-hepatic portal vein gas, suggestive of pneumatosis intestinalis. No free air in the abdominal cavity. Lung cancer did not progress."
      }
    },
    {
      "from": "N13",
      "to": "N14",
      "data": {
        "edge_id": "M_to_N",
        "branch_flag": true,
        "content": "Abdominal computed tomography showed intra-mural gas in the wall of the transverse colon and intra-hepatic portal vein gas in the peripheral area of the liver. White blood cell count was 3500/\u03bcL (normal range: 3400-9200/\u03bcL)"
      }
    }
  ]
}